What are the best treatments for Rasmussen's encephalitis?

Rasmussen's encephalitis is a rare, progressive inflammatory brain disorder primarily managed through long-term immunosuppression and, in many cases, functional hemispherectomy to control intractable seizures. While medical management aims to stabilize the condition, surgical intervention remains the only definitive way to halt the progression of neurological decline in many patients.

What are the primary medical treatments for Rasmussen's encephalitis?

Treatment for Rasmussen's encephalitis is divided into acute stabilization and long-term maintenance. Initial therapy often focuses on reducing inflammation using high-dose corticosteroids (e.g., prednisone, methylprednisolone) and intravenous immunoglobulin (IVIG). To manage ongoing seizures, clinicians frequently prescribe anti-seizure medications, though these often provide limited relief for the drug-resistant epilepsy associated with Rasmussen's encephalitis.

When is surgery recommended for Rasmussen's encephalitis?

Because Rasmussen's encephalitis is a progressive disease, surgery is often considered once the condition is clearly established and the child exhibits significant cognitive or motor deficits. The most effective procedure is a functional hemispherectomy, which involves disconnecting the affected hemisphere from the healthy one to stop seizure spread. While this is a major surgery, it is often the most successful strategy for long-term seizure freedom.

What is the multidisciplinary approach to care?

Managing Rasmussen's encephalitis requires a coordinated team of specialists to address the complex neurological, cognitive, and physical needs of the patient. Essential team members include:

• Pediatric Epileptologists: To manage complex seizure protocols.


• Neurosurgeons: Specialized in pediatric epilepsy surgery.


• Neuroimmunologists: To oversee long-term immunosuppressive therapies.


• Physical and Occupational Therapists: To assist with hemiparesis and motor rehabilitation.


• Neuropsychologists: To monitor cognitive impact and support developmental needs.

How effective are emerging therapies?

Research into Rasmussen's encephalitis continues to evolve, with clinical interest in biologics such as rituximab (Rituxan) and tocilizumab (Actemra) for patients who do not respond to standard steroids. However, data remains limited regarding long-term efficacy, and treatment must be strictly personalized by your medical team based on the patient's specific disease trajectory.

Next steps

• Consult a specialized pediatric epilepsy center or neuroimmunology clinic.


• Connect with the 14 members of the Rasmussen's encephalitis community on DiseaseMaps.org for peer support.


• Maintain a detailed seizure log to assist your neurologist in evaluating treatment responses.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice; always consult your healthcare provider for personalized diagnosis and treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: Portal for rare diseases and orphan drugs


• The Epilepsy Foundation: Rasmussen's Encephalitis resources


• PubMed/NCBI: Clinical literature on hemispherectomy outcomes